Schering-Plough's TEMODAL Capsule for Glioblastoma Multiforme Granted Priority Review by Government.
In Japan, it is estimated that about 2,500 people develop GBM annually, of whom about 2,200 people are diagnosed as anaplastic astrocytoma.
Initially approved in the EU in January 1999, temozolomide is currently approved in 77 countries worldwide.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Nov 2, 2005|
|Previous Article:||Kaken Pharmaceutical to Outsource Entire Distribution Operation to Itochu.|
|Next Article:||National Institute of Technology and Evaluation, Astellas Pharma, Chugai Pharmaceutical to Collaborate in Searching Microorganisms in Vietnam.|